Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 19 Jan 2016 |
| 135,000 Orion Corporation A shares converted into B shares | 9 Dec 2015 |
| Composition of the Nomination Committee of Orion Corporation | 29 Oct 2015 |
| Orion Group Interim Report January-September 2015 | 27 Oct 2015 |
| Publishing of Orion Corporation's Interim Report for January-September 2015 on 27 October 2015 | 13 Oct 2015 |